16th January 2018 Content supplied by: BD Diagnostic Systems
CE Marked Test Detects Common Carbapenemase Genes in Under 2.5 Hours
BD together with Check-Points Health B.V., have obtained CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System.
The BD MAX™ Check-Points CPO assay* provides detection of the five most common carbapenemase genes in less than 2.5 hours, as compared to traditional methods that can take up to 24 hours. Early detection of patients colonized with these organisms can provide the necessary information to implement proper infection control measures. This assay replaces an earlier version of the test from Check-Points, and offers an improved workflow and an additional target.
“We have been using the Check-Points assay on the BD MAX system for routine screening of CPO for nearly two years, because it provides us the information we need to isolate or de-isolate our high-risk patients shortly after admission,” said John Rossen, Assistant Professor of Medical Microbiology at the University Medical Center, Groningen (UMCG) in the Netherlands and scientific secretary of the ESCMID Study Group for Genomic and Molecular Diagnostics. “This assay has not only improved our turn-around-time, but it also gives us the confidence that we will reduce the risk of transmission and outbreak because patient safety is our number one goal.”
Together with BD BBL™ CHROMagar™ CPE plated media* and BD Phoenix™ CPO detect panels*, BD provides comprehensive solutions for screening and infection management to support clinical microbiology laboratories in their AMR programs.
This assay joins BD’s comprehensive healthcare-associated infections diagnostics portfolio, which aims to reduce transmission and outbreak of deadly pathogens. The BD MAX system menu also includes syndromic panels for gastrointestinal infections, as well as reproductive and sexually transmitted infections, which aid laboratory professionals in their efforts to deliver diagnostic results that help enhance patient outcomes, while improving laboratory efficiency. The instrument also features an open system capability, allowing for streamlined workflow of laboratory developed tests and for additional assays via BD partner collaborations.
*Products are not available for sale in the U.S.
Date Published: 16th January 2018
Source article link: View
Resuscitation of Stressed and Injured
Cherwell Publishes In-Depth Guide to